You are here
New Drug Application for Rubitecan Accepted by FDA
The FDA indicated that the user fee goal date for the Orathecin NDA is November 26, 2004. This date is the target date for the completion of the FDA's review and resulting action letter for the filed NDA. The filing contained data on more than 1,000 pancreatic cancer patients who failed at least one prior chemotherapy. Of this population, more than 600 patients received Orathecin and the remainder were given control therapies. SuperGen's Phase III clinical program is believed to be the largest clinical development program in pancreatic cancer ever initiated worldwide.
"Our clinical and regulatory teams worked tirelessly to submit a through and complete NDA and we are gratified that it has been accepted by the FDA," said Dr. James Manuso, Chairman, President and Chief Executive Officer of SuperGen. "Although Orathecin is not a cure, we adamantly believe that it can be of benefit to some patients with pancreatic cancer. We are committed to working with the FDA to bringing this drug to market so that it can help the very patients who need it most."
According to the Pancreatic Cancer Action Network (PanCAN), pancreatic cancer has the highest fatality rate of all cancers. According to American Cancer Society Cancer Facts and Figures 2004, 31,860 people will be diagnosed with pancreatic cancer this year in the United States and 31,270 people will die. Pancreatic cancer is the fourth highest cancer killer in the United States amongst both men and women. The 99 percent mortality rate for pancreatic cancer is the highest of any cancer.
Source: SuperGen Inc.